Vallon V[au] - Search Results

Year	Number of Results
1994	1
1995	5
1996	5
1997	6
1998	7
1999	4
2000	6
2001	4
2002	7
2003	11
2004	8
2005	13
2006	16
2007	9
2008	12
2009	11
2010	9
2011	14
2012	14
2013	5
2014	13
2015	5
2016	10
2017	7
2018	12
2019	8
2020	13
2021	8
2022	10
2023	0

1

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.

Vallon V, Verma S. Vallon V, et al. Annu Rev Physiol. 2021 Feb 10;83:503-528. doi: 10.1146/annurev-physiol-031620-095920. Epub 2020 Nov 16. Annu Rev Physiol. 2021. PMID: 33197224 Free PMC article. Review.

2

Development of SGLT1 and SGLT2 inhibitors.

Rieg T, Vallon V. Rieg T, et al. Among authors: vallon v. Diabetologia. 2018 Oct;61(10):2079-2086. doi: 10.1007/s00125-018-4654-7. Epub 2018 Aug 22. Diabetologia. 2018. PMID: 30132033 Free PMC article. Review.

3

SGLT2 inhibition and kidney protection.

Nespoux J, Vallon V. Nespoux J, et al. Among authors: vallon v. Clin Sci (Lond). 2018 Jun 28;132(12):1329-1339. doi: 10.1042/CS20171298. Print 2018 Jun 29. Clin Sci (Lond). 2018. PMID: 29954951 Free PMC article. Review.

4

The tubular hypothesis of nephron filtration and diabetic kidney disease.

Vallon V, Thomson SC. Vallon V, et al. Nat Rev Nephrol. 2020 Jun;16(6):317-336. doi: 10.1038/s41581-020-0256-y. Epub 2020 Mar 9. Nat Rev Nephrol. 2020. PMID: 32152499 Free PMC article. Review.

5

Renal effects of SGLT2 inhibitors: an update.

Nespoux J, Vallon V. Nespoux J, et al. Among authors: vallon v. Curr Opin Nephrol Hypertens. 2020 Mar;29(2):190-198. doi: 10.1097/MNH.0000000000000584. Curr Opin Nephrol Hypertens. 2020. PMID: 31815757 Free PMC article. Review.

6

Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.

Vallon V, Thomson SC. Vallon V, et al. Diabetologia. 2017 Feb;60(2):215-225. doi: 10.1007/s00125-016-4157-3. Epub 2016 Nov 22. Diabetologia. 2017. PMID: 27878313 Free PMC article. Review.

7

Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.

Qiu H, Novikov A, Vallon V. Qiu H, et al. Among authors: vallon v. Diabetes Metab Res Rev. 2017 Jul;33(5). doi: 10.1002/dmrr.2886. Epub 2017 Feb 23. Diabetes Metab Res Rev. 2017. PMID: 28099783 Review.

8

SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.

Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, Touw D, Hoorn EJ, Nieuwdorp M, Kramer MMH, Joles JA, Bjornstad P, van Raalte DH. Suijk DLS, et al. Among authors: vallon v. Clin J Am Soc Nephrol. 2022 May;17(5):663-671. doi: 10.2215/CJN.11480821. Epub 2022 Mar 23. Clin J Am Soc Nephrol. 2022. PMID: 35322793 Clinical Trial.

9

The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?

Hesp AC, Schaub JA, Prasad PV, Vallon V, Laverman GD, Bjornstad P, van Raalte DH. Hesp AC, et al. Among authors: vallon v. Kidney Int. 2020 Sep;98(3):579-589. doi: 10.1016/j.kint.2020.02.041. Epub 2020 Apr 26. Kidney Int. 2020. PMID: 32739206 Free PMC article. Review.

10

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Tuttle KR, Brosius FC 3rd, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJL, Manley T, McGuire DK, Molitch ME, Mottl AK, Perreault L, Rosas SE, Rossing P, Sola L, Vallon V, Wanner C, Perkovic V. Tuttle KR, et al. Among authors: vallon v. Am J Kidney Dis. 2021 Jan;77(1):94-109. doi: 10.1053/j.ajkd.2020.08.003. Epub 2020 Oct 26. Am J Kidney Dis. 2021. PMID: 33121838

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results